公开(公告)号：JP2013049681A

公开(公告)日：2013-03-14

申请号：JP2012225875

申请日：2012-10-11

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： WAGNER ROLF ,  TUFANO MICHAEL D ,  STEWART KENT D ,  ROCKWAY TODD W ,  RANDOLPH JOHN T ,  PRATT JOHN K ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LONGENECKER KENTON L ,  LIU YAYA ,  LIU DACHUN ,  KRUEGER ALLAN C ,  KATI WARREN M ,  HUTCHINSON DOUGLAS K ,  HUANG PEGGY P ,  FLENTGE CHARLES A ,  DONNER PAMELA L ,  DEGOEY DAVID A ,  BETEBENNER DAVID A ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  HENRY RODGER F ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  SARRIS KATHY ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/513 ,  A61K31/5377 ,  A61P1/16 ,  A61P31/14 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

CPC classification number: A61K31/513 ,  A61K31/5377 ,  C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

Abstract: PROBLEM TO BE SOLVED: To provide compounds useful to treat hepatitis C (HCV) infections.SOLUTION: In the compounds, the uracil or thymine derivative are linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl-phenyl)methanesulfonamide.

Abstract translation: 待解决的问题：提供可用于治疗丙型肝炎（HCV）感染的化合物。 解决方案：在化合物中，尿嘧啶或胸腺嘧啶衍生物通过亚苯连接成稠合的2-环环系（R6），或者通过另外的两个原子连接基（L）连接到5-6元单环（R6 ）。 应用进一步公开了两种特定化合物的多晶型物和假多晶型物：N-（6（3-叔丁基-5-（2,4-二氧代-3,4-二氢嘧啶-1（2H） - 基）2-甲氧基 - 苯基） 萘-2-基）甲磺酰胺和（E）-N-（4（3-叔丁基-5-（2,4-二氧代-3）4-二氢嘧啶-1（2H） - 基）2-甲氧基苯乙烯基 苯基）甲磺酰胺。 版权所有（C）2013，JPO＆INPIT

公开(公告)号：JP2013056886A

公开(公告)日：2013-03-28

申请号：JP2012221886

申请日：2012-10-04

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： FLENTGE CHARLES A ,  HUTCHINSON DOUGLAS K ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  DONNER PAMELA L ,  KATI WARREN M ,  KRUEGER ALLAN C ,  LIU DACHUN ,  LIU YAYA ,  LONGENECKER KENTON L ,  MARING CLARENCE J ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  RANDOLPH JOHN T ,  ROCKWAY TODD W ,  STEWART KENT D ,  WAGNER ROLF ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/506 ,  A61K31/513 ,  A61K45/00 ,  A61P31/14 ,  A61P43/00 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

CPC classification number: C07D239/54 ,  A61K31/513 ,  A61K45/06 ,  C07D239/22 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61K2300/00

Abstract: PROBLEM TO BE SOLVED: To provide anti-infective agents and the like, used either in combination with or in lieu of an interferon agent and/or ribavirin.SOLUTION: This invention relates to: (a) compounds and salts thereof that inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 要解决的问题：提供与干扰素和/或利巴韦林组合或代替干扰素剂和/或利巴韦林使用的抗感染剂等。 本发明涉及：（a）抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。 版权所有（C）2013，JPO＆INPIT

公开(公告)号：WO2006019660A3

公开(公告)日：2006-05-11

申请号：PCT/US2005024447

申请日：2005-07-08

Applicant: ABBOTT LAB ,  BUCKLEY MICHAEL J ,  JI JIANGUO ,  ZHANG GEOFF G ,  HENRY RODGER F ,  WANG WEILI W ,  WAYNE GREG S ,  LI WENKE ,  TOWNE TIMOTHY B ,  WITTENBERGER STEVEN J ,  HANNICK STEVEN M ,  KOTECKI BRIAN J ,  MARCI BRYAN S ,  ROBBINS TIMOTHY A

Inventor： BUCKLEY MICHAEL J ,  JI JIANGUO ,  ZHANG GEOFF G ,  HENRY RODGER F ,  WANG WEILI W ,  WAYNE GREG S ,  LI WENKE ,  TOWNE TIMOTHY B ,  WITTENBERGER STEVEN J ,  HANNICK STEVEN M ,  KOTECKI BRIAN J ,  MARCI BRYAN S ,  ROBBINS TIMOTHY A

IPC: C07D487/04 ,  A61K31/4439

CPC classification number: C07D487/04

Abstract: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.

Abstract translation: 本发明公开了（1S，5S）-3-（5,6-二氯-3-吡啶基）-3,6-二氮杂双环[3.2.0]庚烷及其盐，其用于治疗与 烟碱乙酰胆碱受体。

公开(公告)号：WO2007121339A2

公开(公告)日：2007-10-25

申请号：PCT/US2007066605

申请日：2007-04-13

Applicant: ABBOTT LAB ,  LUKIN KIRILL A ,  CHI-PING HSU MARGARET ,  FERNANDO DILINIE P ,  KOTECKI BRIAN J ,  LEANNA MARVIN R

Inventor： LUKIN KIRILL A ,  CHI-PING HSU MARGARET ,  FERNANDO DILINIE P ,  KOTECKI BRIAN J ,  LEANNA MARVIN R

IPC: A61K31/416 ,  C07D231/56

CPC classification number: C07D231/56

Abstract: The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).

Abstract translation: 本发明涉及制备可用作香草素受体亚型1（VR1）的拮抗剂的吲唑基脲的方法。

公开(公告)号：WO2009117626A3

公开(公告)日：2009-12-23

申请号：PCT/US2009037741

申请日：2009-03-20

Applicant: ABBOTT LAB ,  LUKIN KIRILL A ,  KOTECKI BRIAN J ,  YU SU ,  WANG LEI ,  HAIGHT ANTHONY R

Inventor： LUKIN KIRILL A ,  KOTECKI BRIAN J ,  YU SU ,  WANG LEI ,  HAIGHT ANTHONY R

IPC: C07D231/56 ,  C07D231/54

CPC classification number: C07D231/56

Abstract: The invention discloses compounds of formula ( II ): and methods of making the compounds, which are VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Abstract translation: 本发明公开了式（II）的化合物：以及制备可用于治疗疼痛，炎症性热痛觉过敏，尿失禁和膀胱过度活动的VR1拮抗剂的化合物的方法。

公开(公告)号：EP2012779A4

公开(公告)日：2010-11-24

申请号：EP07760624

申请日：2007-04-13

Applicant: ABBOTT LAB

Inventor： LUKIN KIRILL A ,  CHI-PING HSU MARGARET ,  FERNANDO DILINIE P ,  KOTECKI BRIAN J ,  LEANNA MARVIN R

IPC: A61K31/416 ,  C07D231/56

CPC classification number: C07D231/56

公开(公告)号：EP2323989A4

公开(公告)日：2011-06-22

申请号：EP09722850

申请日：2009-03-20

Applicant: ABBOTT LAB

Inventor： LUKIN KIRILL A ,  KOTECKI BRIAN J ,  YU SU ,  WANG LEI ,  HAIGHT ANTHONY R

IPC: C07D231/56

CPC classification number: C07D231/56

公开(公告)号：AU2014280939A1

公开(公告)日：2015-01-22

申请号：AU2014280939

申请日：2014-12-24

Applicant: ABBOTT LAB

Inventor： KRUEGER ALLAN C ,  GAO YI ,  KOTECKI BRIAN J ,  FLENTGE CHARLES A ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LIU DACHUN ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  BARNES DAVID M ,  HUTCHINSON DOUGLAS K ,  ZHANG GEOFF G Z ,  HENGEVELD JOHN E ,  PRATT JOHN K ,  RANDOLPH JOHN T ,  SARRIS KATHY ,  STEWART KENT D ,  LONGENECKER KENTON L ,  TUFANO MICHAEL D ,  DONNER PAMELA L ,  HUANG PEGGY P ,  HENRY RODGER F ,  WAGNER ROLF ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  ROCKWAY TODD W ,  KATI WARREN M ,  LOU XIAOCHUN ,  LIU YAYA ,  HAUGHT ANTHONY R

IPC: C07D239/22 ,  A61K31/513 ,  A61P31/12 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10

Abstract: URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2,4-dioxo-3,4 dihydropyrimidin-1(2H)-yl)-2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N (4(3-t-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxy-styryl phenyl)methanesulfonamide.

公开(公告)号：CA2699989C

公开(公告)日：2014-03-25

申请号：CA2699989

申请日：2008-09-17

Applicant: ABBOTT LAB

Inventor： DONNER PAMELA L ,  RANDOLPH JOHN T ,  KRUEGER ALLAN C ,  BETEBENNER DAVID A ,  HUTCHINSON DOUGLAS K ,  LIU DACHUN ,  LIU YAYA ,  LONGENECKER KENTON L ,  MARING CLARENCE J ,  PRATT JOHN K ,  ROCKWAY TODD W ,  STEWART KENT D ,  WAGNER ROLF ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK THADDEUS S II ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  HENRY RODGER F ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/506 ,  A61K31/513 ,  A61P31/14 ,  C07D239/54 ,  C07D239/553 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I)

公开(公告)号：AU2013202002A1

公开(公告)日：2013-04-18

申请号：AU2013202002

申请日：2013-03-26

Applicant: ABBOTT LAB

Inventor： KRUEGER ALLAN C ,  GAO YI ,  KOTECKI BRIAN J ,  FLENTGE CHARLES A ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LIU DACHUN ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  BARNES DAVID M ,  HUTCHINSON DOUGLAS K ,  ZHANG GEOFF G Z ,  HENGEVELD JOHN E ,  PRATT JOHN K ,  RANDOLPH JOHN T ,  SARRIS KATHY ,  STEWART KENT D ,  LONGENECKER KENTON L ,  TUFANO MICHAEL D ,  DONNER PAMELA L ,  HUANG PEGGY P ,  HENRY RODGER F ,  WAGNER ROLF ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  ROCKWAY TODD W ,  KATI WARREN M ,  LOU XIAOCHUN ,  LIU YAYA ,  HAIGHT ANTHONY R

IPC: C07D239/22 ,  A61K31/513 ,  A61P31/12 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10

Abstract: URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4 dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E) N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl phenyl)methanesulfonamide.